[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06070285":3,"trial-entities:NCT06070285":84,"trial-summary:NCT06070285":88},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":15,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":26,"secondary_outcomes":33,"sex":34,"minimum_age":35,"maximum_age":15,"healthy_volunteers":36,"eligibility_criteria":37,"std_ages":47,"locations":50,"central_contacts":66,"overall_officials":69,"references":72,"see_also_links":83},"NCT06070285","72827906","Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients","Delving Into the Patterns of Patient Engagement and Trends in Participation Within Recurrent Ovarian Cancer Clinical Trials","NOT_YET_RECRUITING","2026-10","2023-09","2023-10-06","2024-10","Power Life Sciences Inc.","INDUSTRY",null,"Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption.\n\nBy actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.",[18],"Recurrent Ovarian Cancer",[18],"OBSERVATIONAL",[],{"count":23,"type":24},500,"ESTIMATED",[],[27,30],{"measure":28,"timeFrame":29},"Number of patients who decide to participate in a recurrent ovarian cancer clinical trial","3 months",{"measure":31,"timeFrame":32},"Rate of patients who remain in recurrent ovarian cancer clinical research to trial completion","12 months",[],"FEMALE","18 Years",false,{"inclusion":38,"exclusion":42,"raw_text":46},[39,40,41],"Aged ≥ 18 years old","Able to comprehend the investigational nature of the protocol and provide informed consent","Diagnosis of recurrent ovarian cancer",[43,44,45],"No diagnosis of recurrent ovarian cancer confirmed","Inability to perform regular electronic reporting","Patient does not understand, sign, and return consent form","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n* Diagnosis of recurrent ovarian cancer\n\nExclusion Criteria:\n\n* No diagnosis of recurrent ovarian cancer confirmed\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",[48,49],"ADULT","OLDER_ADULT",[51],{"facility":52,"city":53,"state":54,"zip":55,"country":56,"contacts":57,"geoPoint":63},"Power Life Sciences","San Francisco","California","94107","United States",[58],{"name":59,"role":60,"phone":61,"email":62},"Michael B Gill","CONTACT","415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"lat":64,"lon":65},37.77493,-122.41942,[67],{"name":59,"role":60,"phone":61,"email":68},"bask@withpower.com",[70],{"name":59,"affiliation":13,"role":71},"STUDY_DIRECTOR",[73,77,80],{"pmid":74,"type":75,"citation":76},"30887020","BACKGROUND","Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093\u002Fannonc\u002Fmdz104.",{"pmid":78,"type":75,"citation":79},"25728373","Ozga M, Aghajanian C, Myers-Virtue S, McDonnell G, Jhanwar S, Hichenberg S, Sulimanoff I. A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care. 2015 Dec;13(6):1771-80. doi: 10.1017\u002FS1478951515000127. Epub 2015 Mar 2.",{"pmid":81,"type":75,"citation":82},"27798900","Hilal Z, Schultheis B, Hartmann F, Dogan A, Cetin C, Krentel H, Schiermeier S, Tempfer CB. What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature. Anticancer Res. 2016 Oct;36(10):5365-5371. doi: 10.21873\u002Fanticanres.11110.",[],{"nct_id":4,"conditions":85,"biomarkers":87},[86],"Malignant Ovarian Neoplasm",[],{"nct_id":4,"found":89,"summary":90,"prompt_version":100},true,{"design":91,"status":92,"heading":93,"summary":94,"follow_up":95,"word_count":96,"commitments":97,"compensation":98,"drugs_mentioned":99},"This is an observational study, meaning researchers will gather information without providing any specific treatments. It plans to include 500 participants.","completed","Understanding Participation in Recurrent Ovarian Cancer Trials","This study is looking at how people with recurrent ovarian cancer decide to join clinical trials and how long they stay involved. It's an observational study, meaning researchers will watch and learn without giving any specific treatments. They want to understand why some patients choose to participate and others don't, and what helps them complete a trial. You can join if you are 18 or older, have recurrent ovarian cancer, and can understand the study and report information electronically. The goal is to learn more about how to improve participation in future research for this condition. This study aims to enroll 500 participants.","Researchers will track how many patients decide to join a trial at 3 months, and how many remain in research until completion at 12 months.",103,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]